Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS)

Abstract

The 2016 update of the WHO classification has introduced an integrated diagnostic approach that incorporates both tumor morphology and molecular information. This conceptual change has far-reaching implications, especially for neuropathologists who are in the forefront of translating molecular markers to routine diagnostic use. Adult diffuse glioma is a prototypic example for a group of tumors that underwent substantial regrouping, and it represents a major workload for surgical neuropathologists. Hence, we conducted a survey among members of the European Confederation of Neuropathological Societies (Euro-CNS) in order to assess 1) the extent to which molecular markers have already been incorporated in glioma diagnoses, 2) which molecular techniques are in daily use, and 3) to set a baseline for future surveys in this field. Based on 130 responses from participants across 40 nations neuropathologists uniformly rate molecular marker testing as highly relevant and already incorporate molecular information in their diagnostic assessments. At the same time however, the survey documents substantial differences in access to crucial biomarkers and molecular techniques across geographic regions and within individual countries. Concerns are raised concerning the validity of test assays with MGMT, 1p19q, and ATRX; being perceived as most problematic. Neuropathologists advocate the need for international harmonization of standards and consensus guidelines, and the majority is willing to actively engage in interlaboratory trials aiming at quality control (Figure 1). .

Figure 1.. Graphical abstract in response to Ramaswamy and Taylor, Cancer Cell 2016 [1].

Figure 2.. Place of work.

Question 1 – 3.. Responses to questions 1 – 3.

Question 4a.. Response to question 4.

Question 4b.. Response to question 4.

Question 4c.. Response to question 4.

Question 5a.. Response to question 5.

Question 5b.. Response to question 5.

Question 5c.. Response to question 5.

Question 6a.. Response to question 6.

Question 6b.. Response to question 6.

Question 7 – 8.. Responses to questions 7 and 8.

Question 9 – 10.. Responses to questions 9 and 10.